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Introduction: Adjuvant cisplatin-based chemotherapy improves
overall survival; however, chemotherapy compliance has been
difficult. Carboplatin (C) is better tolerated than cisplatin, and
carboplatin-based adjuvant therapy may have better chemother-
apy compliance.
Methods: The primary end point of this multicenter phase II trial
was the feasibility of delivering carboplatin and docetaxel (C/D). An
“adequate exposure” was defined as receiving four cycles of C/D
within 12 weeks of initiating adjuvant therapy. A sample size of 72
patients provided 88% power to detect a true adequate exposure of
rate of at least 80%. Patients with resected non-small cell lung
cancer, a good functional status, and preserved organ function were
eligible. Adjuvant therapy was initiated between 2 and 8 weeks after
surgery, and consisted of four cycles C (area under the curve  6),
and D 75 mg/m2 every 3 weeks.
Results: Seventy-two patients were treated, and the patient demo-
graphics were: median age 65 years (range 47–84), gender male/
female 67%/33%, stage I (40%), II (36%) IIIA (22%) and IIIB (1%),
and the two most common histologies were: adenocarinoma (44%),
and squamous cell carcinoma (42%). Fifty-seven patients (79%)
received four cycles within 12 weeks, and 15 (21%) of patients did
not complete four cycles for the following reasons: adverse events
(n  5), patient refusal (n  5), disease progression during active
therapy (n  3), and intercurrent illness (n  2). No treatment
related deaths were observed and the primary toxicities were hema-
tologic (grade 4 neutropenia 42% and febrile neutropenia 11% of
patients). Twenty-six patients (36%) received growth colony stim-
ulating factor (G-CSF) supportive therapy during their treatment,
and G-CSF supportive therapy was used in 21.6% of all cycles.
Conclusions: C/D has an acceptable toxicity profile with the use of
G-CSF supportive therapy and the majority of patients completed
four cycles of therapy within 12 weeks.
Key Words: Adjuvant chemotherapy, Chemotherapy compliance,
Treatment compliance, Non-small cell lung cancer, Carboplatin,
Docetaxel.
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Lung cancer is the leading cause of cancer death in the UnitedStates, and it is estimated that in 2007, more patients will die
of lung cancer than prostate, colon, and breast cancer com-
bined.1 Non-small cell lung cancer (NSCLC) histology is
responsible for about 85% of the cases, and approximately
45% of patients will present with stage I–IIIA disease.2,3
Surgical resection remains the standard of care of patients
with stage I–II disease, and a subset of patients with stage
IIIA disease. Despite complete surgical resection recurrence
rates are high with the majority of the recurrences being
distant metastases. In 1995, the NSCLC Collaborative Group
reported a meta-analysis that evaluated the efficacy of cispla-
tin-based adjuvant chemotherapy in resected NSCLC.4 This
meta-analysis revealed an absolute survival benefit of 5%
which approached, but did not reach absolute statistical
significance (hazard ratio [HR]  0.87, p  0.08). These
provocative results led to the development of at least five
randomized controlled trials evaluating the efficacy of cispla-
tin-based chemotherapy5–9; three of these trials have revealed
an improvement in overall survival with adjuvant cisplatin-
based therapy.5–7 The recent lung adjuvant cisplatin evalua-
tion (LACE) meta-analysis of the individual patient data from
these five trials revealed a significant improvement in overall
survival with the combination of cisplatin-based chemother-
apy and surgery when compared with surgery alone (HR 
0.89, 95% confidence interval [CI] 0.82, 0.96; p  0.004).10
These trials and the meta-analysis have established the effi-
cacy of adjuvant cisplatin-based therapy.
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Eradication of micrometastatic disease requires an ad-
equate exposure to adjuvant chemotherapy. The successful
delivery of the intended three to four cycles of cisplatin-based
chemotherapy in post-thoracatomy patients has been difficult;
chemotherapy compliance rates have been between 50 and
75% (Table 1). The most common toxicities have been
gastrointestinal (nausea and vomiting) and myelosuppression,
and the rate of treatment-related deaths have been 1 to 2%.
Chemotherapy compliance with cisplatin-based therapy out-
side the context of a clinical trial may be lower, and the
treatment-related toxicity and mortality may be higher.
Two recent meta-analyses which compared cisplatin
and carboplatin-based therapy for advanced NSCLC revealed
a higher rate of  grade 3 nausea and vomiting for cisplatin-
based therapy.11,12 In one meta-analysis there was 1.4-fold
increase in treatment-related death in patients treated with
cisplatin-based versus carboplatin-based therapy (3.9% ver-
sus 2.9%, respectively) which was not statistically significant
(odds ratio  1.36; 95% CI 0.89–2.07).11 Cisplatin-based
chemotherapy produced a higher response rate, but no sig-
nificant improvement in survival when compared with car-
boplatin-based therapy.11,12 In the palliative treatment setting,
the increase in efficacy must be balanced with the increased
toxicity of cisplatin-based therapy. However, in the adjuvant
treatment setting a lower rate of toxicity, in a patient popu-
lation susceptible to toxicity, may result in increased chemo-
therapy compliance and consequently an improvement in overall
survival. Carboplatin and docetaxel is a standard therapy for
advanced NSCLC with an acceptable toxicity profile.13,14 At
the time this trial was designed data on the feasibility of
delivering carboplatin and docetaxel in the adjuvant setting
were not available. Thus, we developed a multicenter phase II
trial designed to investigate the feasibility of delivering four
cycles of adjuvant carboplatin and docetaxel within a 12-
week period.
During the time this trial was being conducted an
interim analysis of Cancer and Leukemia Group B (CALGB)
trial 9633 revealed a survival benefit of adjuvant carboplatin
and paclitaxel when compared with observation in patients
with stage IB NSCLC.15 A subsequent interim analysis re-
vealed a statistically significant difference in disease-free
survival (HR  0.74; 95% CI 0.57–0.96, p  0.03), but no
difference in overall survival (HR  0.80; 95% CI 60–1.07,
p 0.10).16 It is unclear whether the lack of a survival benefit
seen was related to the relatively small size of the trial (n 
344) in a patient population with a lower risk of relapse, due
to the use of carboplatin-based therapy, or potentially a true
lack of overall survival benefit for adjuvant carboplatin-based
therapy in patients with stage IB disease. The LACE meta-
analysis of patients with stage IB disease (n 1371) revealed
a trend toward improved survival with adjuvant cisplatin-
based therapy for patients (HR  0.92, 95% CI 0.78–1.10).10
The Japan Lung Cancer Research Group demonstrated an
improvement in overall survival in patients with pathologi-
cally stage I disease treated with a nonplatinum-based treat-
ment, uracil-tegafur, when compared with observation (HR
0.71; 95% CI 0.52–0.98, p  0.04).17
PATIENTS AND METHODS
Patient Eligibility
Patients were required to have undergone curative re-
section for stage I-IIIA NSCLC, have an Eastern Cooperative
Oncology Group (ECOG) performance status (PS) of1, age
18 years, adequate renal function (defined as a serum
creatinine within upper limit of normal (ULN) or a calculated
creatinine clearance of 40 ml/min), total bilirubin within
ULN, and adequate bone marrow function (defined as an
absolute neutrophil count of 1500/mm3, hemoglobin8 g/dl,
and platelets 100,000/mm3). Patients with elevated alkaline
phosphatase (AP) between 1 and 2.5 X ULN were eligible
if the aspartate aminotransferase (AST) and alanine amino-
transferase (ALT) were 1.5 X ULN. Patients with AP
between 2.5 and 5 X ULN were eligible if the AST or
ALT were within ULN. Patients with a history of a previous
malignancy were eligible if the attending oncologist believed
that adjuvant chemotherapy was indicated and potentially
beneficial to the patient. Patients with an AP, AST, or ALT
5 X ULN, women currently breast-feeding, patients with a
history of severe hypersensitivity to docetaxel or polysorbate
80, and National Cancer Institute (NCI) Common Terminol-
ogy Criteria for Adverse Events (CTCAE) version 3.0 base-
line neuropathy grade 2 were not eligible. Patients signed
informed consent before any study related tests being per-
formed. All patients who met the eligibility criteria were
offered participation in this clinical trial. This protocol was
reviewed by the protocol review committee of Lineberger
Comprehensive Cancer Center, and the Institutional Review
Board of the participating institutions. The investigators were
required to comply with good clinical practice and the prin-
ciples that have their origin in the Declaration of Helsinki.
TABLE 1. Chemotherapy Compliance on Recent Cisplatin-
Based Adjuvant Trials 5–9
Trial N Chemotherapy
No. of
Cycles
Chemotherapy
Compliance
ALPI 1209 MVP 3 69%a
IALT 1867 Cisplatin-basedb 3 or 4 74%c
JBR.10 482 Cisplatin/vinorelbine 4 50%d
ANITA 840 Cisplatin/vinorelbine 4 Cisplatin 76%,
vinorelbine 56%
BLT 381 Cisplatin-basede 3 60%f
a Fifty-one percent of patients who completed the MVP treatment had some dose
adjustment or omission of the planned treatment.
b Treatment was required to be cisplatin-based (80 mg/m2 for 4 cycles, 100 mg/m2 for
3–4 cycles, or 120 mg/m2 for 3 cycles). The most frequently used regimens were (% of
patients receiving treatment): cisplatin/etoposide (49%) and cisplatin/vinorelbine
(27%).
c Percentage of patients received at least a cumulative dose of 240 mg/m2 of
cisplatin.
d Percentage of patients completing 4 cycles of therapy after an amendment
reducing the dosage of vinorelbine from 30 mg/m2/weekly to 25 mg/m2/weekly.
e Patients received one of 4 regimens (% of patents receiving treatment): cisplatin,
mitomycin, vinblastine (42%), cisplatin, mitomycin, ifosfamide (33%), cisplatin, vin-
desine (3%), and cisplatin, vinorelbine (22%).
f Sixty percent of patients received all 3 cycles without a dose reduction of 10%
or a delay of 7 days. Ten percent of patients had a dose reduction, 21% had a dose
delay, and 7% had both.
ALPI, Adjuvant Lung Project Italy; MVP, mitomycin C, vindesine, cisplatin;
ANITA, Adjuvant Navelbine International Trialist Association, JBR.10 National Can-
cer Institute of Canada JBR.10 trial; BLT, Big Lung Trial.
Stinchcombe et al. Journal of Thoracic Oncology • Volume 3, Number 2, February 2008
Copyright © 2008 by the International Association for the Study of Lung Cancer146
Treatment
Patients were required to initiate adjuvant therapy be-
tween 2 and 8 weeks after surgery. Chemotherapy treatment
consisted of carboplatin area under the curve (AUC) of 6
using the Calvert equation18 and docetaxel 75 mg/m2 every
21 days for four cycles. Patients received dexamethasone 4
mg twice a day for 3 days starting 24 hours before the
docetaxel administration. Standard antiemetics therapy was
used, and the selection of the antiemetic agents was at the
discretion of the treating physician. Patients were required to
have an absolute neutrophil count 1500/mm3 and platelet
count of 100,000/mm3 before initiating subsequent chemo-
therapy treatments. Patients experiencing a treatment delay of
2 weeks for any toxicity were taken off the trial. Chemo-
therapy doses were modified one dose level for afebrile grade
4 neutropenia 7 days, grade 4 neutropenia, associated with
a fever, and grade 3 nonhematologic (Table 2). Patients
experiencing grade 4 thrombocytopenia had both drugs re-
duce one dose level (i.e., carboplatin AUC 5, and docetaxel
60 mg/m2), and for a second occurrence of grade 4 throm-
bocytopenia the carboplatin dose was reduced to an AUC 
4, and the docetaxel remained 60 mg/m2. Docetaxel was
withheld for patients with a total bilirubin  ULN until total
bilirubin ULN (for a maximum of 14 days). Docetaxel was
withheld for elevated AP, AST, ALT 5 X ULN until the
liver enzymes recovered (defined as having liver enzymes
that met the eligibility criteria). Patients with persistently
elevated liver enzymes underwent a dose reduction. The
docetaxel dose was reduced one dose level for patients
experiencing NCI CTCAE grade 2 neuropathy, and treatment
was discontinued for patients experiencing grade 3 or 4
neuropathy. If stomatitis was present on day 1 of any cycle
treatment was withheld until stomatitis resolved. The do-
cetaxel dose was reduced one dose level for grade 3 or 4
stomatitis. The protocol recommended that treating physician
follow the American Society of Clinical Oncology (ASCO)
guidelines for the use of growth colony stimulating factors
(G-CSF) and red blood cell growth factors that were available
at the time the protocol was being performed.19,20
Study Design and Statistical Analysis
This trial was a multicenter, single-arm phase II trial
and the primary objective was to evaluate the feasibility of
delivering carboplatin and docetaxel. An “adequate expo-
sure” was defined as a patient receiving four cycles of
adjuvant therapy within 12 weeks of initiating the first dose.
Taking the “null hypothesis” rate of 65% “adequate expo-
sure,” a sample of 72 evaluable patients was required to have
a 88% power to detect a true “adequate exposure” rate of
80%, using a one-sided 2 test. The secondary objectives
were to describe the toxicity associated with adjuvant carbo-
platin and docetaxel, to assess the patterns of recurrence and
survival after adjuvant carboplatin and docetaxel. The toxic-
ity was assessed by the treating physician after each cycle
using the NCI CTCAE version 3.0.
The Kaplan-Meier (or product limit) method was used
to estimate the time to event functions of relapse free survival
and overall survival. Relapse free survival has been defined
as the time between the date of the start of treatment to
disease progression or death (which ever occurs first) or the
date of last contact. Overall survival has been defined as the
time from the date of the start of treatment to the date of death
or the date of last contact. The log-rank test was used to test for
the possible differences between estimated the time to event
curves. Statistical analyses were performed with SAS statistical
software, versions 9.1, SAS Institute Inc., Cary, NC.
RESULTS
Patients
From June 2004 to December 2006, 75 patients were
enrolled on the trial. Three patients withdrew consent before
initiating therapy, and data on the 72 patients who were
enrolled and received treatment on the trial is included in the
patient demographics, and the toxicity and feasibility analy-
sis. The majority of the patient were white (83%), and had a
PS of 0 to 1 (99%) (Table 3). The two most common
histologies were adenocarcinoma and squamous cell car-
cinoma (44% and 42%, respectively), and the majority of
the patients had stage I or II disease (76%). One patient
with stage IIIB (T4N0M0) with a T4 status (based on two
malignant nodules within the same lobe of the lung) was
allowed to enroll on the protocol after an Institutional
Review Board exemption was obtained. One patient with a
PS of 2 was enrolled on the protocol and received four
cycles of therapy. Only 15% of patients had undergone
pneumonectomy.
Treatment Administration
Of the 72 patients enrolled and treated on the trial, 57
(79%) received four cycles of therapy within 12 weeks (Table
4). A total of 15 patients (21%) did not complete four cycles
of therapy. The reasons for discontinuing therapy were:
adverse events (n  5), patient refusal (n  5), disease
progression during active therapy (n  3; abdominal mass
(n  1), and brain metastases (n  2)), intercurrent illness
(n  2)). Twelve patients (17%) had the docetaxel dose
reduced for a total of 21 cycles. The reasons for dose
reduction were: afebrile grade 4 neutropenia 7 days (n 
6), febrile neutropenia (n  4), grade 3 diarrhea (n  1), and
grade 3 dehydration (n  1). Eleven of the 12 patients who
underwent dose reduction completed four cycles of therapy;
five patients had cycle 4, three patients had cycles 3 and 4,
and three patients had the cycles 2, 3, and 4 dose reduced.
One patient underwent one additional cycle of therapy after
dose reduction then discontinued therapy. The number of
TABLE 2. Carboplatin and Docetaxel Dose Modifications
for Toxicity
Dose Level
Docetaxel Dose
(mg/m2)
Carboplatin Dose
(AUC)
0 75 6
1 60 6
2 60 5
3 50 5
AUC, area under the curve.
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patients completing therapy at the full dose within 12 weeks
was 53 (74%). The dose intensity, defined as dose patients
received/intended dose, for carboplatin and docetaxel was
87.5% and 86%, respectively.
Toxicity
The primary toxicity seen on this trial was neutropenia
with 65% of patients developing grade 3 or 4 neutropenia
(Table 5). Forty-two percent of patients developed grade 4
neutropenia and 11% experienced grade 3 or 4 febrile neu-
tropenia. The rate of grade 3 or 4 anemia or thrombocytope-
nia was low; 0% and 1%, respectively. The rate of nonhe-
matologic toxicities was low with the most frequent toxicities
being fatigue/asthenia (5.5%), syncope (5.5%), and docetaxel
infusion related reactions (4%). The use of G-CSF was not
mandated in the protocol; however, 26 (36%) patients re-
ceived G-CSF at some point during the treatment. Eleven
FIGURE 1. Overall survival.
TABLE 5. Treatment-Related Toxicitya (N  72)
Grade
3 (%)
Grade
4 (%)
Grade
3/4 (%)
Hematologic toxicity
Neutropenia 24 42 65
Thrombocytopenia 1 1
Febrile neutropenia 3 8 11
Non-hematologic toxicity
Gastointestinal
Nausea 1 1
Vomiting 1 1
Diarrhea 3 3
Infusional reactions 4 4
Constutional
Dehydration 1 1
Fatigue/asthenia 5.5
Cardiac
Syncope 5.5 5.5
Arrythmiab 1 1
Proteinuria 1 1
Infection 3 3
Dyspnea 1 1
a Worst grade of each individual toxicity reported.
b Supraventricular tachycardia.
TABLE 3. Patient Demographics (N  72)
Parameter
Median age 65 yr (range 47–84 yr)
Ethnicity
White 83% (n  60)
African American 10% (n  7)
Latino 3% (n  2)
Asian 1% (n  1)
Gender (female/male) 33%/67%
Performance status
0 39% (n  28)
1 60% (n  43)
2 1% (n  1)
Stage
I 40% (n  29)
T1N0 8% (n  6)
T2N0 32% (n  23)
II 36% (n  26)
T1N1 12.5% (n  9)
T3N0 3% (n  2)
T2N1 21% (n  15)
IIIA 22% (n  16)
T3N1 3% (n  2)
T1N2 4% (n  3)
T2N2 12.5% (n  9)
T3N2 3% (n  2)
IIIB
T4N0 1% (n  1)
Histology
Adenocarcinoma 44% (n  32)
Squamous cell carcinoma 42% (n  30)
Non-small cell—not otherwise specified 10% (n  7)
Large cell carcinoma 4% (n  3)
Type of surgery
Wedge resection 3% (n  2)
Lobectomy 72% (n  52)
Bi-lobectomy 10% (n  7)
Pneumonectomy 15% (n  11)
TABLE 4. Chemotherapy Compliance
Parameter Percentage (n)
Completed chemotherapy within 12 wk 79 (57)
Dose 74 (53)
After dose reduction 5.5 (4)
Reasons for treatment discontinuation
Adverse events 7 (5)
Patient refusal 7 (5)
Disease progression 4 (3)
Inter-current illness 3 (2)
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patients received G-CSF during the first cycle, and six pa-
tients received it during all four cycles. G-CSF supportive
therapy was used with 54 (21.6%) cycles of therapy.
Survival
Of a total of 72 patients that had been followed for
survival information, only eight have died and 64 were still
alive at the time of analysis (Figure 1). The median follow-up
time for survivors was almost 16 months (range 1–31
months). At the time of the analysis the median survival time
had not been reached, and the overall survival rate at 18
months was 86% (95% CI: 73–93%). Twenty-two survivors
were alive more than 18 months from the date of the start of
treatment. Of the eight patients who have died, five had a
documented relapsed before death. A total of 19 have either
relapsed or died (Figure 2), and the relapse free survival at 18
months was 66% (95% CI: 50–78%). Of the patients who
have experienced relapse, four patients have experienced
intrathoracic relapse, five a combination of intrathoracic and
distant relapse, and 10 patients distant relapse alone, of which
eight were within the brain. The stage distribution of patients
experiencing isolated brain relapse were: stage I (n  2),
stage II (n  2), and stage III (n  4).
DISCUSSION
Although the rate of chemotherapy compliance did not
exactly reach the definition of “adequate exposure” of 80% of
patients receiving for cycles within a 12-week treatment
period, 79% of our patients did complete the treatment with
12 weeks, and 74% completed four cycles at full dose within
12 weeks. The definition of adequate exposure and four
treatment cycles was selected based on the fact that adjuvant
cisplatin-based trials have used four cycles of adjuvant ther-
apy5–7 was based on testing the hypothesis that compliance
with adjuvant carboplatin-based therapy would be superior to
compliance of cisplatin-based therapy seen on previous trials.
The number of cycles and the compliance rate has not been
associated with the efficacy of adjuvant therapy, and thus the
selection of this values was arbitrary. The fact that patients
had to receive the four treatments with 12 weeks (or day 84
after the initiation of chemotherapy) provides accommoda-
tion for dose delays related to treatment related complications
or medical illnesses as well; however, if any single cycle was
delayed for 2 weeks the patient was taken off trial. For
example, a patient could receive his four treatments at 4
weeks intervals (i.e., receive cycles 1–4 on days 1, 28, 56,
and 84, respectively) and still meet the predefined criteria of
completing all four cycles within 12 weeks of receiving the
first treatment.
The chemotherapy compliance seen on this trial was
similar to CALGB 9633 which investigated adjuvant chemo-
therapy with the combination of carboplatin (AUC  6) and
paclitaxel 200 mg/m2 every 3 weeks for four cycles over 12
weeks. Preliminary chemotherapy compliance data from
CALGB 9633 (n  124 patients) revealed 85% of patients
received four cycles of therapy, and 55% received the four
cycles at full dose.15 Adverse event data is available on 158
patients on the CALGB 9633 trial, and grade 3 or 4 toxicities
seen at a rate of 10% were neutropenia (35%) and hyper-
glycemia (15%).16 No treatment related deaths were seen on
CALGB 9633 or our trial.
The chemotherapy compliance seen on this trial compares
favorably to the chemotherapy compliance seen on trials of
cisplatin-based adjuvant therapy which has ranged from 50 to
75% of the intended dose (Table 1). A recent multicenter phase
II trial investigated the feasibility of delivering four cycles of
adjuvant cisplatin and docetaxel.21 Two different docetaxel
schedules were investigated, and the primary end point for this
trial was the amount of cisplatin given over a planned four cycles
of adjuvant therapy.21 Patients on one cohort received docetaxel
35 mg/m2 on days 1, 8, 15, and cisplatin 80 mg/m2 on day 15
every 4 weeks, and patients on the second cohort received
docetaxel 75 mg/m2 and cisplatin 80 mg/m2 on day 1 every 3
weeks. This trial used a two-stage design, and if12 of the first
16 (75%) patients tolerated more than three cycles of therapy the
trial would be stopped. Sixteen patients were treated on the
weekly docetaxel schedule and five of the 16 (31%) were unable
to complete three cycles of therapy, and 11 patients were treated
on the cohort with every 3 week docetaxel, and six of the first 11
(55%) were unable to complete three cycles, and in accordance
with the trial design the trial was discontinued. Among the 11
patients who failed to complete three cycles of chemotherapy the
primary reason was toxicity, and the main toxicities were one or
more of the following: fatigue (n  8), nausea (n  4), febrile
neutropenia (n  1), hypotension (n  1), and nephrotoxicity
(n  1). The fact that chemotherapy compliance was problem-
atic in both cohorts is suggestive that the cisplatin is the primary
agent responsible for the observed toxicity. The intolerance of
the cisplatin and docetaxel combination is in contrast to the
acceptable toxicity and chemotherapy compliance of the carbo-
platin and docetaxel combination seen on our trial.
A multivariate analysis of chemotherapy compliance of
patients treated on the JBR.10 trial revealed factors associ-
ated with chemotherapy compliance were extent of surgery,
gender, age, and patient’s treatment country.22 Patients ran-
domized in Canada were less likely to complete chemother-
apy due to patient refusal than their American counterparts.
FIGURE 2. Relapse-free survival.
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The current trial was performed entirely in the United States,
and was performed after trials revealing the benefits of
adjuvant chemotherapy had been published or presented. This
may have influenced patients and physicians willingness to
tolerate toxicity, and contributed to rate of chemotherapy
compliance observed on this trial. All patients who met the
eligibility criteria were offered the option of participation in
the clinical trial which is our standard practice policy. This
policy reduces the influence of patient selection bias for our
clinical trials; however, subtle forms of physician and patient
selection bias may have influenced enrollment in the trial and
chemotherapy compliance. The fact that patients were treated
on a clinical trial with the specific goal of completing four
cycles of therapy within a 12-week period may influenced
physicians treatment decisions and increased chemotherapy
compliance as well.
On JBR.10 patients who underwent pneumonectomy
were more likely to discontinue therapy because of toxicity
than patients with lesser resections. The percentage of pa-
tients undergoing pneumonectomy was comparable between
the two trials; 54 patients (25%) on JBR.10 and 11 patients
(15%) on our trial. Nine of the 11 patients who underwent
pneumonectomy completed four cycles of therapy; two pa-
tients did not complete therapy due to disease progression.
Female patients were also less likely to complete chemother-
apy on JBR.10 as well. The percentage female patients
receiving adjuvant therapy on JBR.10 was similar to our trial
(36% versus 33%, respectively). Nineteen of the 24 (79%)
female patients on our trial completed four cycles of therapy.
A retrospective analysis of elderly patients (defined as age
65 years) on the JBR.10 trial revealed that adjuvant therapy
provided a survival benefit for elderly patients (HR 0.61; 95%
CI 0.38–0.98; p  0.04).23 However, fewer elderly patients
completed treatment and more refused treatment (p  0.03).23
None of the elderly patients received the full 16 dose of
vinorelbine and only 32% received the intended eight doses
of cisplatin. This data is suggestive that even with a reduced
dose delivery of adjuvant chemotherapy that there is a sur-
vival benefit to treatment and that chemotherapy compliance
in the elderly may be a significant challenge. Sixty-three of
the 213 patients (30%) who received adjuvant chemotherapy
on JBR.10 were age 65. The median age of patients on our
trial was 65 years, and 16 patients (22%) were aged 70
years. Twenty-five of the 33 (76%) patients who were aged
65 years completed four cycles of therapy.
The chemotherapy compliance and toxicity seen with
this adjuvant carboplatin and docetaxel on this trial was
similar to carboplatin and docetaxel in the advanced disease
setting. A randomized phase III trial of carboplatin and
docetaxel in the advanced disease of Fossella et al. revealed
that the median number of cycle of carboplatin and docetaxel
patients received was six, and the relative dose intensity was
93%.13 The percentage of patients experiencing febrile neu-
tropenia and grade 3/4 neutropenia was 4.5% and 74.4%,
respectively. The percentage of patients experiencing of
grade 3 or 4 nonhematologic toxicities on the trial by Fossella
et al. were: (asthenia (10.7%), diarrhea (5.2%), infection
(11%), and pulmonary (13.5%). In a phase II trial by Belani
et al. 85% of patients experienced grade 3/4 neutropenia and
15% experienced febrile neutropenia.14 The most common
nonhematologic toxicity seen was asthenia (24% of patients).
It should be noted that the ASCO recommendations for
the use of G-CSF’s have recently been revised, and the
guidelines recommend primary prophylaxis for the preven-
tion of febrile neutropenia in patients who are at high risk
based on age, medical history, disease characteristics, and
degree and frequency of myelosuppression of the chemother-
apy regimen.24 The current ASCO guidelines recommend that
G-CSF be used when the risk of febrile neutropenia is
approximately 20%. The National Comprehensive Cancer
network (NCCN) guidelines currently consider the combina-
tion of carboplatin and docetaxel to be a high risk (defined as
20% risk for febrile neutropenia) regimen and recommend
the prophylactic use of G-CSF.25 The use of primary prophy-
laxis for febrile neutropenia with G-CSF was not mandated in
this trial; however, the use of G-CSF in 36% of the patients
significantly reduced the rate of grade 3 or 4 neutropenia and
febrile neutropenia, and contributed to the rate of chemother-
apy compliance on this trial. The use of primary prophylaxis
with G-CSF with all cycles of therapy may further reduce the
toxicity, the number of dose reductions, and improvement
chemotherapy compliance further.
The relative efficacy and toxicity of carboplatin and
cisplatin in advanced stage disease has frequently been de-
bated, and two recent meta-analyses have investigated this
issue. A meta-analysis by Hotta et al. revealed a statistically
significant survival advantage for cisplatin in combination
with third-generation regimens when compared with carbo-
platin in combination with third-generation regimens (HR 
1.106, 95% CI  1.005–1.218; p  0.039).11 A separate
meta-analysis using individual patient data revealed that in
patients treated with platinum in combination with third-
generation agents, patients receiving cisplatin had a superior
survival when compared with patients receiving carbopla-
tin.12 These differences in carboplatin and cisplatin efficacy
may have limited clinical implications in the palliative set-
ting, but significant clinical implications when treating in the
curative setting. However, a more active regimen that cannot
be delivered due to toxicity in the patient population of
interest may erode its advantage over less active regimens.
Certainly cisplatin-based therapy should be considered the
standard given the results of recent phase III trials and the
LACE meta-analysis. However, many patients are not opti-
mal candidates for cisplatin-based therapy or may experience
excessive toxicity. Although carboplatin-based chemotherapy
should be considered investigational we believe it remains an
option for patients who can not tolerate cisplatin-based ther-
apy. We believe the issue of the optimal choice of platinum
agents (cisplatin versus carboplatin) in the adjuvant setting is
worthy of a phase III trial. The upcoming ECOG adjuvant
trial, ECOG 1505, will evaluate the efficacy of cisplatin-
based chemotherapy with and without bevacizumab, and the
three chemotherapy combinations that will be used will be
cisplatin/vinorelbine, cisplatin/docetaxel, and cisplatin/gem-
citabine.26 This trial should provide valuable information
Stinchcombe et al. Journal of Thoracic Oncology • Volume 3, Number 2, February 2008
Copyright © 2008 by the International Association for the Study of Lung Cancer150
about the potential efficacy of bevacizumab and third gener-
ation cisplatin combinations in the adjuvant setting.
CONCLUSION
In conclusion, the combination of carboplatin and do-
cetaxel has an acceptable toxicity profile with the use of
G-CSF supportive therapy in the adjuvant setting, and the
primary toxicities are hematologic. The majority of patients
completed the four cycles of therapy within 12 weeks. We
believe that adjuvant therapy with carboplatin and docetaxel
in patients who have contraindications to cisplatin or patient
populations with poor chemotherapy compliance is a reason-
able alternative.
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